Recent studies have provided evidence implicating lysophosphatidic acid (LPA) signaling through its G protein-coupled receptor, LPA1, as a mechanism of macrophage activation that correlates with the onset of relapses and greater disease severity in both EAE and MS [189]. Here, LPAR1 is linked to myeloid sarcoma.